Zentalis Pharmaceuticals, Inc. (ZNTL)
4.105
+0.34
(+8.89%)
USD |
NASDAQ |
Sep 03, 16:00
4.07
-0.04
(-0.85%)
After-Hours: 20:00
Zentalis Pharmaceuticals Research and Development Expense (TTM) : 116.32M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 116.32M |
| March 31, 2026 | 108.76M |
| December 31, 2025 | 106.14M |
| September 30, 2025 | 109.63M |
| June 30, 2025 | 123.50M |
| March 31, 2025 | 144.28M |
| December 31, 2024 | 167.77M |
| September 30, 2024 | 186.35M |
| June 30, 2024 | 196.29M |
| March 31, 2024 | 190.59M |
| December 31, 2023 | 189.59M |
| September 30, 2023 | 178.65M |
| June 30, 2023 | 174.06M |
| March 31, 2023 | 175.21M |
| Date | Value |
|---|---|
| December 31, 2022 | 172.73M |
| September 30, 2022 | 170.56M |
| June 30, 2022 | 173.57M |
| March 31, 2022 | 174.52M |
| December 31, 2021 | 166.80M |
| September 30, 2021 | 157.88M |
| June 30, 2021 | 137.36M |
| March 31, 2021 | 110.04M |
| December 31, 2020 | 84.90M |
| September 30, 2020 | 67.25M |
| June 30, 2020 | 53.32M |
| March 31, 2020 | 44.56M |
| December 31, 2019 | 38.39M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| ARS Pharmaceuticals, Inc. | 15.23M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |
| Savara, Inc. | 86.84M |